{"id":16209,"date":"2019-09-30T09:05:08","date_gmt":"2019-09-30T07:05:08","guid":{"rendered":"https:\/\/www.satt.fr\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/"},"modified":"2019-09-30T09:05:08","modified_gmt":"2019-09-30T07:05:08","slug":"un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/","title":{"rendered":"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer"},"content":{"rendered":"<p><strong>La SATT Nord et la soci\u00e9t\u00e9 Apmonia Therapeutics ont sign\u00e9 une licence exclusive pour l\u2019exploitation d\u2019un peptide innovant en oncologie<\/strong><\/p>\n<p>Des travaux de recherche men\u00e9s au cours des derni\u00e8res ann\u00e9es ont montr\u00e9 que le r\u00e9cepteur cellulaire CD47 favorise la progression tumorale en agissant comme un int\u00e9grateur de signaux pro-canc\u00e9reux r\u00e9gulant des processus biologiques vari\u00e9s.<br \/>\nEn particulier, l\u2019activation de CD47 par la TSP-1 (thrombospondine-1) joue un r\u00f4le cl\u00e9 dans les processus angiog\u00e9niques et dans la r\u00e9ponse immunitaire, faisant ainsi de l\u2019interaction TSP-1:CD47 une cible pharmacologique d\u2019int\u00e9r\u00eat pour le d\u00e9veloppement d\u2019outils th\u00e9rapeutiques contre la progression tumorale et la diss\u00e9mination m\u00e9tastatique.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-18761 alignleft\" src=\"https:\/\/sattnord.fr\/wp-content\/uploads\/2019\/09\/apmonia-345x191.jpg\" alt=\"\" width=\"370\" height=\"208\" \/>Dans ce contexte, les recherches men\u00e9es depuis 2008 au sein de l\u2019UMR CNRS 7369 MEDyC de l\u2019Universit\u00e9 de Reims Champagne-Ardenne par une \u00e9quipe de chercheurs compos\u00e9e notamment du Pr. St\u00e9phane DEDIEU et du Dr. Albin JEANNE ont permis de d\u00e9velopper un nouveau peptide antagoniste inhibant la fixation de la TSP-1 sur son r\u00e9cepteur CD47 (le peptide TAX2), r\u00e9duisant la vascularisation des tumeurs, induisant une r\u00e9ponse anti-m\u00e9tastatique ainsi que l\u2019activation d\u2019une r\u00e9ponse immunitaire dirig\u00e9e contre les cellules canc\u00e9reuses.<br \/>\nLa SATT Nord a financ\u00e9 la maturation du projet initi\u00e9 par l\u2019\u00e9quipe du Pr. St\u00e9phane DEDIEU, permettant de consolider et d\u2019\u00e9tendre la preuve de concept pour l\u2019usage th\u00e9rapeutique de ce candidat m\u00e9dicament.<\/p>\n<p>Suite \u00e0 ces r\u00e9sultats prometteurs, la jeune entreprise r\u00e9moise Apmonia Therapeutics dirig\u00e9e par Albin JEANNE et incub\u00e9e chez Innovact (membre du r\u00e9seau SEMIA) a sign\u00e9 une licence exclusive portant sur l\u2019exploitation des brevets relatifs \u00e0 l\u2019utilisation th\u00e9rapeutique du peptide TAX2.<\/p>\n<p>La soci\u00e9t\u00e9 Apmonia Therapeutics est une soci\u00e9t\u00e9 de biotechnologie ayant pour vocation le d\u00e9veloppement de strat\u00e9gies d\u2019immunoth\u00e9rapie anticanc\u00e9reuses. Ses objectifs sont d\u2019acc\u00e9l\u00e9rer les d\u00e9veloppements pr\u00e9cliniques r\u00e9glementaires et cliniques du peptide TAX2, tout en maintenant une activit\u00e9 de recherche et d\u00e9veloppement permettant de renforcer les actifs de la soci\u00e9t\u00e9.<\/p>\n<p><a href=\"https:\/\/sattnord.fr\/wp-content\/uploads\/2019\/09\/CP-APMONIA-final.pdf\"><strong>T\u00e9l\u00e9charger le communiqu\u00e9 de presse\u00a0<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La SATT Nord et la soci\u00e9t\u00e9 Apmonia Therapeutics ont sign\u00e9 une licence exclusive pour l\u2019exploitation d\u2019un peptide innovant en oncologie Des travaux de recherche men\u00e9s au cours des derni\u00e8res ann\u00e9es ont montr\u00e9 que le r\u00e9cepteur cellulaire CD47 favorise la progression tumorale en agissant comme un int\u00e9grateur de signaux pro-canc\u00e9reux r\u00e9gulant des processus biologiques vari\u00e9s. En [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":16196,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567],"tags":[],"class_list":["post-16209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline BRILLANT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/\"},\"author\":{\"name\":\"Caroline BRILLANT\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/cfc3546ad932d078cb047ce83a0742ea\"},\"headline\":\"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer\",\"datePublished\":\"2019-09-30T07:05:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/\"},\"wordCount\":380,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/\",\"url\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/\",\"name\":\"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg\",\"datePublished\":\"2019-09-30T07:05:08+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/cfc3546ad932d078cb047ce83a0742ea\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg\",\"width\":4608,\"height\":2556},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/cfc3546ad932d078cb047ce83a0742ea\",\"name\":\"Caroline BRILLANT\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/caroline-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/","twitter_misc":{"Written by":"Caroline BRILLANT","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/"},"author":{"name":"Caroline BRILLANT","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/cfc3546ad932d078cb047ce83a0742ea"},"headline":"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer","datePublished":"2019-09-30T07:05:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/"},"wordCount":380,"image":{"@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/","url":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/","name":"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg","datePublished":"2019-09-30T07:05:08+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/cfc3546ad932d078cb047ce83a0742ea"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/09\/apmonia.jpg","width":4608,"height":2556},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/un-nouveau-candidat-medicament-dans-la-lutte-contre-le-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"SATT Nord : Un nouveau candidat m\u00e9dicament dans la lutte contre le cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/cfc3546ad932d078cb047ce83a0742ea","name":"Caroline BRILLANT","url":"https:\/\/www.satt.fr\/en\/author\/caroline-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/16209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=16209"}],"version-history":[{"count":0,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/16209\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/16196"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=16209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=16209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=16209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}